
The study assesses selected cardiorenal outcomes with ertugliflozin using a baseline glucose‐lowering agent. VERTIS CV was a cardiovascular (CV) outcome trial for ertugliflozin vs placebo, conducted in patients with type 2 diabetes and established atherosclerotic cardiovascular disease (ASCVD). In VERTIS CV, the effects of ertugliflozin on cardiorenal outcomes were consistent across subgroups of patients stratified by baseline glucose‐lowering agent.
Like
Save
Share